Back to Search Results
Back to Results
Melanoma / Skin
General Information
Study Name:
CemiplimAb Survivorship Epidemiology (CASE)
Age Group:
Adult
Protocol Number:
NCT0383610
Background Information:
This is a prospective survivorship study of adult patients with Cutaneous Squamous cell Carcinoma (CSCC) who receive treatment with commercially available cemiplimab. The objectives of the study are to identify potential determinants of disease progression, Quality of Life (QOL), and other health-related outcomes. The study also looks to assess patient experience, QOL and functional status, in a real-world setting for patients with CSCC. The information collected from the study will be used to better understand the long-term effectiveness and safety of cemiplimab-rwlc in patients. Cemiplimab-rwlc has been approved by the U.S. FDA for treatment of advanced cutaneous squamous cell carcinoma.
Offered at:
Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital
Eligibility Information
Adult male and/or female subjects between the ages of 18 and 70 years receiving treatment with cemiplimab for CSCC, or initiating treatment with cemiplimab for CSCC
Additional eligibility in protocol
Ineligibility Information
Patients receiving cemiplimab for an indication other than CSCC
Additional ineligibility in protocol
Contact Information
Contact Name:
Hunfa Asghar
Contact Phone:
571-472-0626
Contact Email:
hunfa.asghar@inova.org